...Thank you, operator. I hope everyone is having a great afternoon. At MannKind, our mission is to give people control of their health and the freedom to live the life, and what we call that is life more humann. We're really excited about our first quarter highlights of 2023. Number one, our UT collaboration is strong. Patient demand has driven royalty revenue growth of 29% versus Q4 '22. We're currently undergoing manufacturing capacity expansion, which I'll talk later in this call. Our pipeline is quickly moving ahead with inhaled clofazimine going into adaptive Phase II/III and we had a very successful pre-IND meeting with FDA on MannKind-201, in which we received written comments on how to proceed. Our endocrine business, underlying business is strong with Afrezza growing 26% versus 2022, and we had sequential growth over Q4 versus the traditional decline that we see in the new year. Additionally, we're kicking off our first large Phase IV trial in INHALE-3 called Pumps Sparing, which...
